Retropubic versus perineal radical prostatectomy in early prostate cancer: Eight‐year experience

Martis, Gianni; Diana, Massimo; Ombres, Maurizio; Cardi, Antonio; Mastrangeli, Roberta; Mastrangeli, Bruno

doi:10.1002/jso.20714

Cited by 27 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systematic reviews suggested some problems with the reliability of the observational evidence and in some cases the methods of synthesis do not appear to be robust. Of the three RCTs, only the trial reported by Martis and colleagues 114 provided longer-term outcome data (biochemical recurrence); the others focussed on perioperative outcomes. 115,116 The time to biochemical recurrence survival curves reported for PRP and RRP in Martis and colleagues 114 are almost identical, hence we assumed no difference in biochemical recurrence-free survival between the two procedures.…”

Section: Case Study 1: Full Guideline Model For Prostate Cancermentioning

confidence: 99%

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Lord

Willis²,

Eatock³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

Section: Case Study 1: Full Guideline Model For Prostate Cancermentioning

confidence: 99%

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Lord

Willis²,

Eatock³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

“…Prostate cancer is the most common malignancy and the second leading cause of cancer death in men (1). Active treatment is usually recommended for patients with localized disease and a long life expectancy, with radical prostatectomy (RP) being shown to be superior to other treatments in appropriate patients.…”

Section: Introductionmentioning

confidence: 99%

“…Active treatment is usually recommended for patients with localized disease and a long life expectancy, with radical prostatectomy (RP) being shown to be superior to other treatments in appropriate patients. Because the urologists always seek less invasive and less morbid therapeutic options and the financial sources supplying health worldwide tend Clinical Urolo�y Clinical Urolo�y doi: 10.1590/S1677-55382010000600007 to support therapeutic modalities resulting in shorter hospitalization and early recovery, interest in radical perineal prostatectomy (RPP) has increased again in recent years (1,2). When compared to radical retropubic prostatectomy (RRP), laparoscopic or roboticassisted procedures have advantageous outcome data regarding duration of hospitalization, loss of blood, time needed to recover from the disease, and return to normal daily life (3).…”

Section: Introductionmentioning

confidence: 99%

“…When compared to radical retropubic prostatectomy (RRP), laparoscopic or roboticassisted procedures have advantageous outcome data regarding duration of hospitalization, loss of blood, time needed to recover from the disease, and return to normal daily life (3). However, these advantages may also be offered by RPP, which additionally has some advantages such as lesser cost and shorter duration of operation (1,4). RPP also presents an optimal exposure for apical dissection and urethrovesical anastomosis (4).…”

Section: Introductionmentioning

confidence: 99%

“…However, there are few studies of a limited number of patients exploring the effect of RPP on early urinary continence in the literature (1,2). In this study, we evaluated urinary continence data of our localized prostate cancer cases who had undergone RPP by single surgeon.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Radical perineal prostatectomy and early continence: outcomes after 120 cases

Albayrak¹,

Cangüven²,

Göktaş³

et al. 2010

Int. braz j urol.

View full text Add to dashboard Cite

Purpose: Evaluate the results of urinary continence on patients who had undergone radical perineal prostatectomy (RPP) for clinically localized prostate cancer. Materials and Methods:We analyzed the continence data of 120 patients with pathology of cT1-cT2N0M0 prostate cancer and who had undergone RPP. Continence was assessed on the day of catheter removal, at the end of the first and third month, and the first year postoperatively. The patients who were continent immediately after catheter removal were classified in the group of "immediately continent" while the patients who became continent during the 3 postoperative months were classified as "early continent." Results: Mean duration of catheterization was 10 (10-25) days. Of 120 patients, 44 (36.7%) were immediately continent. At the end of the first and third months, 65 (54.1%) and 87 (72.5%), respectively, were early continent. At the one-year follow-up, 95.3% of 107 cases whose one-year follow-up data were available were continent. When the relationship between patients' age and continence was analyzed, it was found that the early continence rates were 77.7% (7/9), 73.3% (33/45), 73.4% (36/49), and 64.7% (11/17) in the groups of ≤ 49, 50-59, 60-69, and ≥ 70 years, respectively (p = 0.68). Conclusions: The majority of patients who underwent RPP rapidly regained continence within 3 months. RPP is an exceptional alternative approach for radical surgery in the treatment of localized prostate cancer.

show abstract

Neoplasms of the Prostate

Logothetis

Kim

Davis

et al. 2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Cancer of the prostate is the most commonly diagnosed nonskin neoplasm and the second leading cause of cancer‐related mortality in men in the United States. Considerable advances have been made in screening, diagnosis, and therapy options, particularly in advanced disease, but controversies about the diagnosis and management of prostate cancer, especially in the areas of screening and choice of therapy, continue to evolve. Controversies in advanced disease states have shifted from prognostication to prediction, and current treatment considerations are focused on optimization of sequence or combinations of therapy, determining the role of local control and bone targeting. It is anticipated that addressing these knowledge gaps will lead to an integrated and more effective treatment strategies. Further advances in therapy can be achieved by development of new agents with unique mechanisms of action and rational integration into combination therapies. Prostate cancer awareness, clinical application of improved biopsy schemes, and advances in imaging combined with the widespread use of prostate‐specific antigen (PSA) have resulted in increased detection of prostate cancer. The evolving use of the serum PSA concentration and its change over time have not been paralleled by studies that tested the relevance of those findings until the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were first published in 2009. Though many of the apparent discrepancies between these trials can be accounted for by trial design and patient cross‐contamination, they brought to the forefront the dilemma of overdiagnosis and overtreatment and the urgent need to improve the accuracy of clinically significant prostate cancer. It is hoped that replacement of the current morphologic and anatomic classification of prostate cancer with one based on improved understanding of biology will lead to molecular classification and bring closer a personalized management of this complex disease. Salient features that distinguish prostate cancer from other malignancies and that frame the dilemmas surrounding it are its striking age‐dependent incidence, with progressively increasing frequency with increasing age; the variable lethality of morphologically identified cancers; the central role of androgen signaling; and the preponderance of bone‐forming metastases on its lethal progression. The important advances made in each of these areas will, in the near future, modify the approaches currently used to prevent, prognosticate, and treat prostate cancer.

show abstract

Retropubic versus perineal radical prostatectomy in early prostate cancer: Eight‐year experience

Abstract: Radical perineal prostatectomy is an excellent alternative approach for radical surgery in the treatment of early prostate cancer.

Cited by 27 publications

References 45 publications

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Radical perineal prostatectomy and early continence: outcomes after 120 cases

Neoplasms of the Prostate

Contact Info

Product

Resources

About